NCT01240642终止1 期
A Multi-center, Open-label, Dose-escalation Study in Patients With Advanced Cacner to Determine the Effect of the ASA404 Infusion Rate and Co-administration With the Paclitaxel Plus Carboplatin Regimen or Docetaxel on the Pharmacokinetics of Free and Total ASA404
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 27
- 试验地点
- 1
- 主要终点
- To evaluate the pK of a single intravenous dose of ASA404 1200 and 1800 mg/m2 monotherapy in adult cancer patients with impaired renal function compared to matching patients with normal renal function
研究概览
简要总结
The purpose of this study is to determine the effect of the ASA404 infusion rate and co-administrating ASA404 with paclitaxel + carbopaltin chemotherapy regimen or docetaxel on the pharamcokinetics (PK) of free and total ASA404.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients having histologically-proven solid tumors, who are either refractory to standard chemotherapy
- •Patients whom chemotherapy with an investigaional agent in combination with docetaxel, or paclitaxel + carboplatin is appropriate
- •Creatinine clearance according to Cockcroft-Gault formula : Normal > 80 mL/min, Mild 50-80 mL/min, Moderate 30-<50 mL/min
- •A minimum of 4 weeks must have elapsed since the last treatment with other cancer therapies
- •Potassium, calcium, magnesium and phosphorus values within the normal range
- •Body Mass Index (BMI) must be within the range of 18 and 30
排除标准
- •Patients having CNS metastases, must have a CT or MRI of the brain performed to rule out CNS metastases
- •Patients with leptomeningeal disease metastases
- •Radiotherapy </- weeks prior to starting study drug
- •Major surgery </ 4 weeks prior to the start of study
- •Administration of CYP1A2 and CYP3A4/5 enzyme inducing or inhibiting drugs within 14 days prior to starting study drug
- •Other protocol-defined inclusion/exclusion criteria may apply
研究组 & 干预措施
ASA404
Experimental
干预措施: ASA404 (Drug)
结局指标
主要结局
To evaluate the pK of a single intravenous dose of ASA404 1200 and 1800 mg/m2 monotherapy in adult cancer patients with impaired renal function compared to matching patients with normal renal function
时间窗: 12 monnths
次要结局
- To evaluate the pharmacokinetics of a single i.v. dose of ASA 1200 and 1800 mg/m2 +chemotherapy (doctaxel or paclitaxel + carboplatin) in adult cancer patients with impaired renal function compared to matching patients with normal renal function(12 months)
- To evaluate ASA404 pharmacokinetic parameters including AUC (0-t last),), AUC (0-inf)), T ((½)), CL, V(Z), Cmax, and Tmax(12 months)
- To assess the safety and tolerability of ASA404 in adult cancer patients with impaired renal function compared to matching patients with normal renal function(12 months)
- To evaluate renal clearance (CLR) of ASA404.(12 months)
- To assess the safety and tolerability of ASA404 1200 or 1800 mg/m2 in combination with chemotherapy (docetaxel or paclitaxel + carboplatin)(12 months)
研究者
研究点 (1)
Loading locations...
相似试验
终止
1 期
A Dose-escalation Pharmacokinetic Study of Intravenous ASA404 in Adult Advanced Cancer Patients With Impaired Renal Function and Patients With Normal Renal FunctionMetastatic CancerNCT01278758Novartis Pharmaceuticals7
已完成
1 期
Study of ASN004 in Patients With Advanced Solid TumorsSolid TumorNCT04410224Kirilys Therapeutics Inc.19
已完成
1 期
An Open-label, Phase I Trial of Intravenous ASA404 Administered in Combination With Paclitaxel and Carboplatin in Japanese Patients With Non-Small Cell Lung Cancer (NSCLC)Non-small Cell Lung CancerNCT00674102Novartis Pharmaceuticals15
终止
1 期
A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid LeukemiaAcute Myeloid LeukemiaNCT02954653Pfizer8
终止
1 期
Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell CarcinomaRenal Cell CarcinomaNCT03393936Shanghai PerHum Therapeutics Co., Ltd.66